Literature DB >> 17265405

Severity of Clostridium difficile-associated disease (CDAD) in allogeneic stem cell transplant recipients: evaluation of a CDAD severity grading system.

Erik R Dubberke1, Justin Sadhu, Robert Gatti, Kimberly A Reske, John F DiPersio, Steven M Devine, Victoria J Fraser.   

Abstract

The purpose of this study was to develop and test a Clostridium difficile-associated disease (CDAD) grading system based on presenting symptoms in allogeneic stem cell transplant recipients. Patients with severe CDAD had significantly shorter median survival times and more adverse outcomes than patients with mild or moderate CDAD.

Entities:  

Mesh：

Year:  2007        PMID： 17265405     DOI： 10.1086/511792

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN： 0899-823X            Impact factor:   3.254


  13 in total

Review 1.  Clostridium difficile infection among hematopoietic stem cell transplant recipients: beyond colitis.

Authors:  Carolyn D Alonso; Kieren A Marr
Journal:  Curr Opin Infect Dis       Date:  2013-08       Impact factor: 4.915

Review 2.  Clostridium difficile: deleterious impact on hematopoietic stem cell transplantation.

Authors:  Alejandro Callejas-Díaz; Juan C Gea-Banacloche
Journal:  Curr Hematol Malig Rep       Date:  2014-03       Impact factor: 3.952

Review 3.  Clostridioides difficile Infection in the Stem Cell Transplant and Hematologic Malignancy Population.

Authors:  Elizabeth Ann Misch; Nasia Safdar
Journal:  Infect Dis Clin North Am       Date:  2019-06       Impact factor: 5.982

4.  Clostridium difficile-associated disease in allogeneic hematopoietic stem-cell transplant recipients: risk associations, protective associations, and outcomes.

Authors:  Erik R Dubberke; Kimberlay A Reske; Anand Srivastava; Justin Sadhu; Robert Gatti; Rebecca M Young; Lauren C Rakes; Brian Dieckgraefe; John DiPersio; Victoria J Fraser
Journal:  Clin Transplant       Date:  2009-07-13       Impact factor: 2.863

5.  Clostridium difficile Infection (CDI) in Solid Organ and Hematopoietic Stem Cell Transplant Recipients.

Authors:  Carolyn D Alonso; Mini Kamboj
Journal:  Curr Infect Dis Rep       Date:  2014-08       Impact factor: 3.725

6.  A Single-Center Experience and Literature Review of Management Strategies for Clostridium difficile Infection in Hematopoietic Stem Cell Transplant Patients.

Authors:  Aneela Majeed; Marti M Larriva; Ahmad Iftikhar; Adeela Mushtaq; Patrick Campbell; Mustafa Nadeem Malik; Abdul Rafae; Muhammad Abu Zar; Ahmad Kamal; Midhat Lakhani; Nageena Rani Khalid; Tirdad T Zangeneh; Faiz Anwer
Journal:  Infect Dis Clin Pract (Baltim Md)       Date:  2020-01

7.  Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials.

Authors:  Derrick W Crook; A Sarah Walker; Yin Kean; Karl Weiss; Oliver A Cornely; Mark A Miller; Roberto Esposito; Thomas J Louie; Nicole E Stoesser; Bernadette C Young; Brian J Angus; Sherwood L Gorbach; Timothy E A Peto
Journal:  Clin Infect Dis       Date:  2012-08       Impact factor: 9.079

8.  Procalcitonin levels associate with severity of Clostridium difficile infection.

Authors:  Krishna Rao; Seth T Walk; Dejan Micic; Elizabeth Chenoweth; Lili Deng; Andrzej T Galecki; Ruchika Jain; Itishree Trivedi; Marie Yu; Kavitha Santhosh; Cathrin Ring; Vincent B Young; Gary B Huffnagle; David M Aronoff
Journal:  PLoS One       Date:  2013-03-07       Impact factor: 3.240

9.  Clinical risk factors for severe Clostridium difficile-associated disease.

Authors:  Timothy J Henrich; Douglas Krakower; Asaf Bitton; Deborah S Yokoe
Journal:  Emerg Infect Dis       Date:  2009-03       Impact factor: 6.883

10.  Incidence of diarrhea by Clostridium difficile in hematologic patients and hematopoietic stem cell transplantation patients: risk factors for severe forms and death.

Authors:  Fernanda Spadão; Juliana Gerhardt; Thais Guimarães; Frederico Dulley; João Nóbrega de Almeida Junior; Marjorie Vieira Batista; Maria Aparecida Shikanai-Yasuda; Anna Sara Levin; Silvia Figueiredo Costa
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2014 Jul-Aug       Impact factor: 1.846
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.